Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.48 |
| ▸ | NR3C2 | P08235 | 6/20 | 0.48 |
| ▸ | PGR | P06401 | 3/20 | 0.47 |
| ▸ | GUSB | P08236 | 12/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3491958 | 0.86 | KMT2A (0.54) | NR3C1NR3C2PGRCYP3A4MEN1 | |
| SCHEMBL3490963 | 0.82 | KMT2A (0.50) | NR3C1NR3C2PGRCYP3A4MEN1 | |
| SCHEMBL3490784 | 0.82 | HPGD (0.47) | CA2NR3C1NR3C2PGRGUSB | |
| SCHEMBL3488988 | 0.82 | MEN1 (0.50) | NR3C1NR3C2PGRCYP3A4MEN1 | |
| SCHEMBL9272679 | 0.80 | NR3C1 (0.48) | NR3C1NR3C2PGRGUSBCYP3A4 | |
| SCHEMBL3489252 | 0.80 | MEN1 (0.54) | NR3C1NR3C2PGRMEN1KMT2A | |
| SCHEMBL3491178 | 0.79 | LMNA (0.52) | CA2NR3C1NR3C2PGRCYP3A4 | |
| SCHEMBL3488511 | 0.79 | CA12 (0.52) | NR3C1NR3C2PGRCYP3A4MEN1 | |
| SCHEMBL3490966 | 0.77 | TP53 (0.57) | NR3C1NR3C2PGRCYP3A4MEN1 | |
| SCHEMBL3490432 | 0.75 | CYP19A1 (0.48) | NR3C1NR3C2PGRCYP3A4MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035866-A1 | NOVEL SUBSTITUTED-1, 1-DIOXO-BENZO[1,2,4]THIADIAZIN-3ONES, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | OPRD1, HTR6, HTR1D | CA2 4878/4885NR3C1 247/4885NR3C2 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.